Trending...
- A New Era Of Social Networking Is Here !
- Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
SAN DIEGO, June 17, 2024 ~ In a recent announcement, Primrose Bio, Inc. revealed that it has received a significant equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment will provide the necessary funds for the company to further develop and expand its three major offerings.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
- Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
- Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Filed Under: Business
0 Comments
Latest on The PennZone
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- Brother Marcus Celebrates 400th Episode of The Elements of Inspiration Podcast
- USA Dental Edge Unveils Dental Intelligence
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- An AI Plays Kenshi Entirely by Itself, Live 23 Hours a Day, With an AI Host and Chat Voting
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
- Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
- Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board